Neuberger Berman Group LLC Grows Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Posted by Defense World Staff on Jun 8th, 2023

Neuberger Berman Group LLC grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 1,161.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 60,770 shares of the biopharmaceutical company’s stock after purchasing an additional 55,952 shares during the quarter. Neuberger Berman Group LLC’s holdings in Alnylam Pharmaceuticals were worth $14,442,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Geode Capital Management LLC increased its position in shares of Alnylam Pharmaceuticals by 5.7% during the 4th quarter. Geode Capital Management LLC now owns 1,689,929 shares of the biopharmaceutical company’s stock valued at $401,144,000 after purchasing an additional 90,455 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S increased its holdings in Alnylam Pharmaceuticals by 93.5% in the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 5,630 shares of the biopharmaceutical company’s stock worth $1,338,000 after acquiring an additional 2,721 shares in the last quarter. American Century Companies Inc. increased its holdings in Alnylam Pharmaceuticals by 1.0% in the 4th quarter. American Century Companies Inc. now owns 699,795 shares of the biopharmaceutical company’s stock worth $166,306,000 after acquiring an additional 6,788 shares in the last quarter. CIBC Private Wealth Group LLC increased its holdings in Alnylam Pharmaceuticals by 2.1% in the 4th quarter. CIBC Private Wealth Group LLC now owns 121,866 shares of the biopharmaceutical company’s stock worth $28,961,000 after acquiring an additional 2,458 shares in the last quarter. Finally, Fund Management at Engine No. 1 LLC increased its holdings in Alnylam Pharmaceuticals by 17.5% in the 4th quarter. Fund Management at Engine No. 1 LLC now owns 1,355 shares of the biopharmaceutical company’s stock worth $322,000 after acquiring an additional 202 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on ALNY shares. HC Wainwright reissued a “buy” rating and issued a $415.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, March 3rd. Sanford C. Bernstein started coverage on shares of Alnylam Pharmaceuticals in a report on Tuesday, March 21st. They issued an “outperform” rating and a $243.00 target price for the company. JPMorgan Chase & Co. reduced their target price on shares of Alnylam Pharmaceuticals from $200.00 to $196.00 and set a “neutral” rating for the company in a report on Friday, March 3rd. BMO Capital Markets raised shares of Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $200.00 to $250.00 in a report on Friday, May 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $240.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, February 24th. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $247.20.

Alnylam Pharmaceuticals Stock Down 1.4 %

Shares of ALNY opened at $190.17 on Thursday. The company has a market cap of $23.68 billion, a PE ratio of -21.88 and a beta of 0.48. The business has a fifty day moving average of $199.15 and a 200 day moving average of $210.58. Alnylam Pharmaceuticals, Inc. has a 52-week low of $122.57 and a 52-week high of $242.97.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last issued its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.97) by $0.57. The company had revenue of $319.29 million during the quarter, compared to the consensus estimate of $312.53 million. Alnylam Pharmaceuticals had a negative return on equity of 1,287.80% and a negative net margin of 93.13%. Alnylam Pharmaceuticals’s revenue was up 49.7% on a year-over-year basis. During the same period last year, the company earned ($2.00) earnings per share. As a group, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.46 earnings per share for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CMO Pushkal Garg sold 1,839 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, April 27th. The stock was sold at an average price of $194.59, for a total transaction of $357,851.01. Following the completion of the sale, the chief marketing officer now directly owns 6,800 shares in the company, valued at $1,323,212. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CMO Pushkal Garg sold 1,839 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, April 27th. The stock was sold at an average price of $194.59, for a total transaction of $357,851.01. Following the completion of the sale, the chief marketing officer now directly owns 6,800 shares in the company, valued at $1,323,212. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Jeffrey V. Poulton sold 977 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, April 27th. The stock was sold at an average price of $194.59, for a total value of $190,114.43. Following the sale, the chief financial officer now owns 11,706 shares of the company’s stock, valued at $2,277,870.54. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 17,799 shares of company stock worth $3,517,442. 1.40% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Company Profile

(Get Rating)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.